Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
SB 11285
i
Other names:
SB 11285, SB-11285, SB11285
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Sino Biopharm
Drug class:
STING agonist
Related drugs:
‹
CS-1018 (2)
XMT-2056 (2)
CS-1010 (1)
CS-1020 (1)
TAK-500 (1)
ACTM-838 (0)
ADU-S100 (0)
BI 1387446 (0)
E7766 (0)
GSK3745417 (0)
IMSA101 (0)
MK-2118 (0)
ONM-501 (0)
SYNB1891 (0)
TSN222 (0)
TAK-676 (0)
exoSTING (0)
MK-1454 (0)
CS-1018 (2)
XMT-2056 (2)
CS-1010 (1)
CS-1020 (1)
TAK-500 (1)
ACTM-838 (0)
ADU-S100 (0)
BI 1387446 (0)
E7766 (0)
GSK3745417 (0)
IMSA101 (0)
MK-2118 (0)
ONM-501 (0)
SYNB1891 (0)
TSN222 (0)
TAK-676 (0)
exoSTING (0)
MK-1454 (0)
›
Associations
News
Trials
Filter by
Latest
14d
Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=61, Completed, invoX Pharma Limited | Active, not recruiting --> Completed | N=146 --> 61 | Trial completion date: Dec 2024 --> Jul 2024 | Trial primary completion date: Dec 2024 --> Jul 2024
14 days ago
Trial completion • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation
|
Tecentriq (atezolizumab) • SB 11285
4ms
Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=146, Active, not recruiting, invoX Pharma Limited | Recruiting --> Active, not recruiting | Trial completion date: Mar 2027 --> Dec 2024 | Trial primary completion date: Mar 2027 --> Dec 2024
4 months ago
Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
BRAF (B-raf proto-oncogene)
|
Tecentriq (atezolizumab) • SB 11285
9ms
Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=146, Recruiting, invoX Pharma Limited | Phase classification: P1a/1b --> P1 | Trial completion date: Oct 2025 --> Mar 2027 | Trial primary completion date: Oct 2023 --> Mar 2027
9 months ago
Phase classification • Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation
|
Tecentriq (atezolizumab) • SB 11285
over1year
Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1a/1b, N=146, Recruiting, F-star Therapeutics, Inc. | N=110 --> 146 | Trial completion date: May 2022 --> Oct 2025 | Trial primary completion date: Dec 2021 --> Oct 2023
over 1 year ago
Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation
|
Tecentriq (atezolizumab) • SB 11285
over4years
[VIRTUAL] A phase I/Ib dose-escalation study of intravenously administered SB 11285 alone and in combination with nivolumab in patients with advanced solid tumours (ESMO 2020)
Funding: Spring Bank Pharmaceuticals. Clinical trial identification: NCT04096638.
over 4 years ago
Clinical • P1 data • Combination therapy • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • STING (stimulator of interferon response cGAMP interactor 1)
|
Opdivo (nivolumab) • SB 11285
over4years
[VIRTUAL] A phase Ia/Ib dose-escalation study of intravenously administered SB 11285 alone and in combination with nivolumab in patients with advanced solid tumors. (ASCO 2020)
The trial is being conducted at multiple sites in the U.S . Research Funding: Spring Bank Pharmaceuticals, Inc.
over 4 years ago
Clinical • P1 data • Combination therapy • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • STING (stimulator of interferon response cGAMP interactor 1)
|
Opdivo (nivolumab) • SB 11285
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login